At GSK, we are creating an agile and more competitive Pharma business equipped to win in a dynamic external environment by improving our pipeline and performance. We will prioritize taking rapid, decisive action to focus the portfolio and accelerate timelines across four core areas to maintain or build global leadership (Respiratory, HIV/ Infectious Disease, Oncology, and Immuno-Inflammation). Our integrated Pharma business will become a more competitive organization: R&D, Manufacturing, and Commercial will combine to simplify decision-making and increase efficiency. Plus, we will continue to be a ‘force for good’ driven equally by competitive performance and our values.
Reporting to the Vice President, Precision Medicine (PMed) Portfolio Planning - Development, the Executive Director, PMed Portfolio Planning will sit at the heart of the organization bringing extensive biomarker testing knowledge expertise to inform disease area diagnostic testing strategy to maximize GSK portfolio commercial value.
This individual will embed deep understanding of the rapidly evolving global biomarker diagnostic testing ecosystem and partner with asset leads to guide the execution of the precision medicine strategy in priority markets. In addition, you will develop precision medicine knowledge tools to build infrastructure for access to quality testing for patient diagnosis, to inform treatment selection and response monitoring.
Together with the VP PMed Portfolio Planning you will serve as a resource to Business Development, Medical and Commercial Biomarker Teams to help inform key partnerships and post-launch biomarker strategies. You will also stay current in technical and scientific advances related to precision medicine and serve as an industry thought leader within TA related to biomarkers through publications and advocacy organization.
Key Responsibilities:
Early identification and communication of business risks, support the development of mitigation plans and scenario planning.
Responsible for the implementation of Target Test Profiles across the portfolio for those assets that require precision medicine solutions to inform and guide precision medicine decisions within R&D.
Responsible for integrating target test profiles within regions.
Execute landscape assessment to deliver Asset Diagnostic (Dx) Strategy & Diagnostics Playbook.
Deliver current ideal testing journey/pathway - identify gaps and leverage points that need to be addressed by early market shaping activities & develop mitigation plans across care path. Identify root causes for gaps/barriers in testing infrastructure, single or multi-technology approach; laboratory developed test (LDT) vs in vitro diagnostic medical device (IVD) vs companion diagnostics (CDx).
Drive early HCS Dx shaping activities and partnerships across regions (e.g. ring study, concordance study, educational activities, etc).
Together with Medical Affairs, deliver Scientific Testing Narrative with why, who, how & when to test.
Inform Dx needs to evidence generation studies, including data on testing modalities and technical considerations, diagnostic clinical utility, use and treatment outcomes.
Drive diagnostic consensus, position paper and/or guidelines by leveraging key medical experts to propose "optimal" testing pathway.
Implement clinical laboratory External Quality Assurance (EQA) initiatives.
Responsible for the creation and implementation of the PMed Diagnostic Fact Book for timely biomarker testing knowledge transfer from development to medical affairs and commercial.
Create, expand and foster a network of precision medicine subject matter experts including external expert advisors that inform strategic and tactical business decisions.
Enable effective partnership between GSK Global, Regional and LOC commercial and Medical Affairs to Diagnostic partners.
Responsible for identifying appropriate data sources and partnerships to advance precision medicine strategies for the disease area and/or priority assets.
Stay current in technical and scientific advances related to precision medicine and serve as an industry thought leader within TA related to biomarkers through publications and advocacy organization.
In partnership across PMed groups build deep understanding of the global diagnostic ecosystem. The scope will include new technologies, regulatory, reimbursement, policy dynamics, patient & testing journeys, competitor positioning across different market archetypes.
Foster a culture of collaboration and delivery with clear accountability.
Why you?
Basic Qualifications:
Bachelor’s Degree in life sciences required.
15 years + industry experience in precision medicine across therapeutic areas.
10 years + prior precision medicine tools/diagnostics development and commercialization experience with understanding of diagnostics business models.
Prior experience in global, region and country launch of Drug/Dx products and companion diagnostics.
Commercial leadership experience in the development of diagnostics strategies and business planning.
Experience with business development and alliance management.
Leadership and management experience, including budgetary responsibility.
Preferred Qualifications:
Advanced degree in life sciences/medicine (MSc, PhD, PharmD and/or MBA).
Managerial experience directly managing people and/or leadership experience leading teams.
Strong network within the precision medicine space.
Excellent communication, negotiation, and influencing skills.
Proven ability to prioritize tasks and deliver high-quality results under tight deadlines.
Engages confidently, impactfully, and professionally within broad organizational environments.
Core Competencies:
Leadership: Ability to inspire teams, mentor individuals, and allocate resources strategically.
Strategic Thinking: Capable of developing and executing strategies that maintain competitive advantage.
Business Acumen: Understands the business implications of decisions and leverages resources effectively.
Project Management: Proficient in risk-based planning and resource management to achieve project goals.
#J-18808-Ljbffr
#J-18808-Ljbffr
